Difference between revisions of "RiskEvidenceSynthesis FHIR Resource Proposal"
(migrate to Confluence) |
|||
| (6 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
<div class="messagebox cleanup metadata"> | <div class="messagebox cleanup metadata"> | ||
| − | <div style="float: left;">[[Image:OpenHotTopic.GIF|35px| ]]</div> | + | Current version: https://confluence.hl7.org/display/FHIR/RiskEvidenceSynthesis+FHIR+Resource+Proposal<div style="float: left;">[[Image:OpenHotTopic.GIF|35px| ]]</div> |
<div style="background:#F0F0F0"> | <div style="background:#F0F0F0"> | ||
This page documents a [[:category:Pending FHIR Resource Proposal|Pending]] [[:category:FHIR Resource Proposal|FHIR Resource Proposal]] | This page documents a [[:category:Pending FHIR Resource Proposal|Pending]] [[:category:FHIR Resource Proposal|FHIR Resource Proposal]] | ||
| Line 33: | Line 33: | ||
==Committee Approval Date:== | ==Committee Approval Date:== | ||
| − | June 22, 2018 | + | |
| + | *Initial PSS: June 22, 2018 | ||
| + | *CDS WG: September 12, 2018 | ||
==Contributing or Reviewing Work Groups== | ==Contributing or Reviewing Work Groups== | ||
<!-- Additional work groups that may have an interest in contributing to, or reviewing the content of the resource (optional) --> | <!-- Additional work groups that may have an interest in contributing to, or reviewing the content of the resource (optional) --> | ||
| − | * Clinical Decision Support | + | *Clinical Decision Support |
| − | * Clinical Quality Information | + | *Clinical Quality Information |
| − | * Biomedical Research and Regulation | + | *Biomedical Research and Regulation |
==FHIR Resource Development Project Insight ID== | ==FHIR Resource Development Project Insight ID== | ||
| Line 110: | Line 112: | ||
The effect estimates that may be reported from this example include: | The effect estimates that may be reported from this example include: | ||
| − | * Mean reduction of 4.6 points in a score | + | |
| − | * Relative risk increase of 50% (or risk ratio 1.5) for the risk of headache | + | *Mean reduction of 4.6 points in a score |
| − | * Absolute risk increase of 2% (or risk difference 0.02) for the risk of headache | + | *Relative risk increase of 50% (or risk ratio 1.5) for the risk of headache |
| + | *Absolute risk increase of 2% (or risk difference 0.02) for the risk of headache | ||
The risk estimates that may be reported could include: | The risk estimates that may be reported could include: | ||
| − | * with Superdrug -- mean Stressiness score of 13.2, and risk of headache of 6% | + | |
| − | * with Placebo -- mean Stressiness score of 17.8, and risk of headache of 4% | + | *with Superdrug -- mean Stressiness score of 13.2, and risk of headache of 6% |
| + | *with Placebo -- mean Stressiness score of 17.8, and risk of headache of 4% | ||
The RiskEvidenceSynthesis resource describes: | The RiskEvidenceSynthesis resource describes: | ||
| − | * the point estimate for the risk or specific value with one exposure (without comparison to or difference from an alternative exposure) | + | |
| − | * classification of the risk type (continuous or dichotomous, mean, median, proportion, etc.) | + | *the point estimate for the risk or specific value with one exposure (without comparison to or difference from an alternative exposure) |
| − | * a precision estimate (such as 95% confidence intervals) | + | *classification of the risk type (continuous or dichotomous, mean, median, proportion, etc.) |
| − | * rating of certainty of the risk estimate | + | *a precision estimate (such as 95% confidence intervals) |
| − | * descriptions of the population (eg Stressitis), exposure (eg Superdrug or Placebo), and outcome (eg. Stressiness Score, or risk of headache) that the risk estimate is about | + | *rating of certainty of the risk estimate |
| − | * descriptions of the source of the risk estimate (eg author, citation, type of research, sample size) | + | *descriptions of the population (eg Stressitis), exposure (eg Superdrug or Placebo), and outcome (eg. Stressiness Score, or risk of headache) that the risk estimate is about |
| + | *descriptions of the source of the risk estimate (eg author, citation, type of research, sample size) | ||
EXAMPLE 2 IN THE CONTEXT OF RISK ESTIMATE AS PRIMARY FOCUS | EXAMPLE 2 IN THE CONTEXT OF RISK ESTIMATE AS PRIMARY FOCUS | ||
| Line 142: | Line 147: | ||
| − | The | + | The RiskEvidenceSynthesis resource will reference: |
| − | * | + | |
| − | * citation (an expected resource for future proposal) | + | *PicoElementDefinition |
| + | *citation (an expected resource for future proposal) | ||
==Resource Boundaries== | ==Resource Boundaries== | ||
| Line 154: | Line 160: | ||
To be determined if implementers have questions that need explanations to support distinction and clarification. | To be determined if implementers have questions that need explanations to support distinction and clarification. | ||
| − | + | EffectEvidenceSynthesis is about the difference (or "effect") between an exposure and alternative exposure state on an outcome in a population. RiskEvidenceSynthesis is about the "risk" of an outcome with an exposure state in a population. RiskEvidenceSytnhesis does not include an alternative exposure state of difference between states. | |
==Timelines== | ==Timelines== | ||
| Line 167: | Line 173: | ||
brynrhodes (github user) | brynrhodes (github user) | ||
| + | |||
KhalidShahin-EBSCO (github user) | KhalidShahin-EBSCO (github user) | ||
Latest revision as of 15:28, 31 October 2019
This page documents a Pending FHIR Resource Proposal
Contents
- 1 RiskEvidenceSynthesis
- 1.1 Owning work group name
- 1.2 Committee Approval Date:
- 1.3 Contributing or Reviewing Work Groups
- 1.4 FHIR Resource Development Project Insight ID
- 1.5 Scope of coverage
- 1.6 RIM scope
- 1.7 Resource appropriateness
- 1.8 Expected implementations
- 1.9 Content sources
- 1.10 Example Scenarios
- 1.11 Resource Relationships
- 1.12 Resource Boundaries
- 1.13 Timelines
- 1.14 gForge Users
- 1.15 When Resource Proposal Is Complete
- 1.16 FMG Notes
RiskEvidenceSynthesis
Owning work group name
Committee Approval Date:
- Initial PSS: June 22, 2018
- CDS WG: September 12, 2018
Contributing or Reviewing Work Groups
- Clinical Decision Support
- Clinical Quality Information
- Biomedical Research and Regulation
FHIR Resource Development Project Insight ID
1422
Scope of coverage
The scope of the RiskEvidenceSynthesis resource is to describe the likelihood of an outcome in a population with an exposure where the risk estimate is derived from the combination of research studies. Risk estimates are not effects and do not represent a difference between exposure states.
Expressing risk estimates is done throughout reporting of biomedical research, systematic reviews, and clinical reference across all disciplines.
Risk estimates as a "synthesis" of research studies is a different concept for risk estimation than risk estimates for an individual person.
RIM scope
Resource appropriateness
Across the evidence-based medicine community (hundreds of thousands of people communicating the results of healthcare research through systematic reviews and expressing the findings from a body of evidence), the risk estimate synthesized from a body of evidence is the primary method of expressing quantitative results. Standardization is necessary to support interoperability across the evidence-based medicine domain.
Expected implementations
Many knowledge producers who express the biomedical research community knowledge will be the implementers using this resources. Examples of these knowledge producers include Agency for Healthcare Research and Quality (AHRQ), Centers for Disease Control and Prevention (CDC), Cochrane, Duodecim Medical Publications Ltd (from the Finnish Medical Society), EBSCO Health, MAGIC (stands for Making GRADE the Irresistible Choice), and numerous guideline development organizations.
Content sources
None expected beyond the standard source specifications. However, the method for expressing citations (eg referring to a publication) is not yet defined and may require additional source specifications.
Example Scenarios
EXAMPLE 1 IN THE CONTEXT OF SUPPORTING AN EFFECT ESTIMATE SYNTHESIS
A systematic review and meta-analysis combines 17 trials comparing Superdrug against Placebo in 12,356 study participants with Stressitis and finds that Superdrug reduces the Stressiness Score by a mean of 4.6 points but increases headache by 50% (ie 4% of people taking Placebo and 6% of people taking Superdrug had a headache).
The effect estimates that may be reported from this example include:
- Mean reduction of 4.6 points in a score
- Relative risk increase of 50% (or risk ratio 1.5) for the risk of headache
- Absolute risk increase of 2% (or risk difference 0.02) for the risk of headache
The risk estimates that may be reported could include:
- with Superdrug -- mean Stressiness score of 13.2, and risk of headache of 6%
- with Placebo -- mean Stressiness score of 17.8, and risk of headache of 4%
The RiskEvidenceSynthesis resource describes:
- the point estimate for the risk or specific value with one exposure (without comparison to or difference from an alternative exposure)
- classification of the risk type (continuous or dichotomous, mean, median, proportion, etc.)
- a precision estimate (such as 95% confidence intervals)
- rating of certainty of the risk estimate
- descriptions of the population (eg Stressitis), exposure (eg Superdrug or Placebo), and outcome (eg. Stressiness Score, or risk of headache) that the risk estimate is about
- descriptions of the source of the risk estimate (eg author, citation, type of research, sample size)
EXAMPLE 2 IN THE CONTEXT OF RISK ESTIMATE AS PRIMARY FOCUS
A systematic review and meta-analysis combines 13 studies reporting the risk of Tuberculosis in people with HIV Infection who are exposed to Homelessness. The focus is determining the risk (eg is this a high-risk group for screening?) rather than the measure of the effect of homelessness.
Resource Relationships
The RiskEvidenceSynthesis resource will reference:
- PicoElementDefinition
- citation (an expected resource for future proposal)
Resource Boundaries
To be determined if implementers have questions that need explanations to support distinction and clarification.
EffectEvidenceSynthesis is about the difference (or "effect") between an exposure and alternative exposure state on an outcome in a population. RiskEvidenceSynthesis is about the "risk" of an outcome with an exposure state in a population. RiskEvidenceSytnhesis does not include an alternative exposure state of difference between states.
Timelines
First STU Ballot 2019 May
gForge Users
brynrhodes (github user)
KhalidShahin-EBSCO (github user)
When Resource Proposal Is Complete
When you have completed your proposal, please send an email to FMGcontact@HL7.org
